Eden Innovations Ltd · ASX:EDE
Eden Innovations — Investor Presentation (March 2017)
35 slides from Eden Innovations's investor presentation, Mar 10, 2017
Slide 1: US Investor Presentation
For personal use only US Investor Presentation 9 March 2017 EDE. ASX
Slide 2: Disclaimer
Disclaimer 2 FORWARD LOOKING STATEMENTS For personal use only This presentation includes certain forward-looking statements of Eden’s management. Forward-looking statements are statements that contemplate the happening of possible future events and are not based on historical fact. Forward-looking s
Slide 3: Company Highlights
Company Highlights 3 For personal use only . Innovations that work. EDE.ASX
Slide 4: Capital Structure
Capital Structure 4 For personal use only Issuer Eden Innovations Limited Symbol/ Exchange EDE. ASX Issued shares 1,257,854,928 Stock Price (1) A$0.305 Market Cap (1) ≈A$434 million (2) Cash (1) ≈A$14 million Debt Nil 1) As of 7 March 2017 2) Incl EDEO 211m Ex @ 3c 30.9.18 Innovations that work. EDE
Slide 5: Board of Directors and Senior Management
Board of Directors and Senior Management 5 For personal use only Board of Directors • Greg Solomon LLB - Executive Chairman • Richard Beresford BSc (Mech Eng), MSc (Technology and Development) FAICD, FAIE • Guy Le Page BA, BSc(Hons), MBA, ASIA, MAusIMM • Doug Solomon LLB (Hons), B. Juris. Company Se
Slide 6: Company Products
Company Products 6 For personal use only Innovations that work. EDE.ASX
Slide 7: Carbon Nanotubes (CNT) in Concrete
Carbon Nanotubes(CNT) in Concrete For personal use only 7 • Tensile Strength: 200-300x steel • Weight: ≈ 17% of steel • Strengthens concrete, plastics TEM image of Eden’s MWCNT •CNT provide: Nucleation points for dense, cement hydration that builds on surface of CNT (see image) Ultra-strong nano
Slide 8: Product comparison of concrete additives and drawbacks
Increases Increases Increases Reduces Reduces Increases 8 Products Compres Split- Flexural Shrinkage Permeability Abrasion Drawback sive Tensile Strength Resistance Strength Strength For personal use only None Fibers Reduced workability, (PP,PVA,ACRY,LOK) difficult to handle Shrinkage Reducers Stren
Slide 9: CNT in Concrete Applications
9 CNT in Concrete Applications For personal use only Increased Abrasion Resistance Lower Permeability / Lower Increased Compressive Shrinkage and Tensile Strength Road & bridges surfaces Roads, bridges, runways High rise buildings, bridges, Coastal and marine applications retaining walls, pre-fabric
Slide 10: U.S and Australian Concrete Trials 2015-16
10 U.S and Australian Concrete Trials 2015-16 For personal use only EdenCrete® Reference Innovations that work. EDE.ASX
Slide 11: U.S and Australian Concrete Trials 2015-16
U.S and Australian Concrete Trials 2015-16 11 For personal use only EdenCrete® Reference Innovations that work. EDE.ASX
Slide 12: ASTM C494 "S" – Completed
ASTM C494 “S” – Completed 12 For personal use only Testing by Intelligent Concrete LLC. Intelligent Concrete is entitled to receive royalties on sales of EdenCrete® % Increase of EdenCrete®®(3.5 gal/yd3) Over Reference Age (Days) Test 1 3 7 28 56 90 180 365 Compressive Strength (ASTM C39) 25% 35% 39
Slide 13: EdenCrete – Abrasion Resistance
EdenCrete® – Abrasion Resistance 13 For personal use only EdenCrete® Reference Innovations that work. EDE.ASX
Slide 14: GDOT I-20 Field Trial
14 GDOT I-20 Field Trial For personal use only August 2015 Improvement with EdenCrete® • Compressive Strength - 45.8% at 56 days • Abrasion resistance - 56% at 56 days Outcomes • GDOT - approval to use - 24hr repair mix / B class concrete - First contract -February 2017 - 2nd Field Trial - class A c
Slide 15: GDOT I-20 Field Trial – Update October 2016
15 GDOT I-20 Field Trial – Update October 2016 For personal use only EdenCrete® – No Visible Cracking Control – Visible Crack Across Slab Innovations that work. EDE.ASX
Slide 16: Anticipated Cumulative Cost Comparison
16 Anticipated Cumulative Cost Comparison* For personal use only Cost Benefit Analysis Projected Extra Cost For GDOT GDOT costs /yd3 ≈ 3% - 20% Application Rate will vary for different targeted applications Anticipated Increased Service Life >100% Anticipated IRR < 50%+ Using EdenCrete®
Slide 17: Anticipated Cumulative Cost Comparison
17 Anticipated Cumulative Cost Comparison* For personal use only $45,000 $40,000 $35,000 $30,000 $25,000 $20,000 $15,000 $10,000 $5,000 $0 0 10 20 30 40 Years REFERENCE CONCRETE EDENCRETE500 * Based on GDOT actual costs for I-20 Field Trial Innovations that work. EDE.ASX
Slide 18: EdenCrete Performance versus Dose
EdenCrete® Performance versus Dose (Gallons per Yard) 18 Dosage Abrasion Compressive Flexural Tensile Shrinkage For personal use only Gallons/yd³ * Resistance 1/8 15% 5% 7% 5% 6% 1/4 17% 7% 12% 13% 18% 1/2 19% 9% 16% 31% 22% 1 19% 11% 21% 33% 24% 2 28% 16% 27% 40% 27% 3 27% 26% 33% 43% 29% 4 41% 32%
Slide 19: EdenCrete – First Commercial Project
19 EdenCrete® – First Commercial Project For personal use only Ultra High Wear /Abrasion Resistance Application Control Trial Slab Typical Ultra High Load EdenCrete Trial Slab Significant cracks and High loading/ abrasive No cracks of evidence of wear after 6 months application at site wear Innovati
Slide 20: EdenCrete – First Commercial Project
20 EdenCrete® – First Commercial Project For personal use only Ultra High Wear/Abrasion Resistance Application • 50% thickness vs new ultra high strength slab • Only EdenCreteTM used (no steel mesh or rebar) • No significant sub-base preparations • At least a comparable 5-year service life expected
Slide 21: First Commercial EdenCrete Infrastructure Contract
First Commercial EdenCrete® Infrastructure Contract 21 Georgia MARTA Bus Garage – Atlanta, GA For personal use only Innovations that work. EDE.ASX
Slide 22: First Commercial EdenCrete Infrastructure Project
First Commercial EdenCrete® Infrastructure Project 22 For personal use only Georgia MARTA Bus Garage • Results – Dosage rate: 3 gallons/ yard³ Compressive Strength Increase - 38% Split Tensile Strength Increase - 59% Modulus of Elasticity Increase - 24% Abrasion Resistance Increase - 47% S
Slide 23: U.S Marketing Update – Initial Targets
U.S Marketing Update – Initial Targets 23 Interstate Highways (≈73,000km*) / Bridges (≈605,000) For personal use only • Use ≈40% of U.S cement * • ≈$40 billion p.a. preservation/maintenance bill ** • 146,418 or 24% of bridges are structurally deficient/ functionally obsolete *** • Annual extra costs
Slide 24: U.S Infrastructure Marketing - Georgia
U.S Infrastructure Marketing - Georgia 24 • GDOT - Approved and now specified for road repairs For personal use only - First contract for repairs- I-16 February 2017 - Field trial for new road construction / whitetopping- March 2017 - Discussing bridge applications - 14,700 bridges - 2,600 structura
Slide 25: U.S Infrastructure Marketing – Other Progress
25 U.S Infrastructure Marketing – Other Progress For personal use only US State DOTs other than GDOT • Approval process started with other DOTs for roads and bridges • Trials for precast bridge beams commenced in Texas • Approval for use in further state DOTs likely in 2016 and 2017 - ASTM C494 “S”
Slide 26: Other DOT Approval Status
26 Other DOT Approval Status For personal use only • Approval applications lodged in 10 SASHTO states: Alabama, Arkansas, Florida, Kentucky, Louisiana, Mississippi, N. Carolina, S. Carolina, Texas, West Virginia • Approval received from Arkansas and Tennessee DOTs • Texas- to be sought on completio
Slide 27: Precast Concrete Trials- Texas
27 Precast Concrete Trials- Texas For personal use only Innovations that work. EDE.ASX
Slide 28: U.S Sales and Marketing
U.S Sales and Marketing 28 For personal use only Sales Team – Coverage of All Continental U.S • Senior Vice President of Business Development appointed • 9 sales staff – 2 managers / 6 salespeople/ 1 technical sales support Over 20 Trials across US - Infrastructure and Non- Infrastructure • Pervious
Slide 29: U.S Production Scale-Up
U.S Production Scale-Up 29 Location Est. Cost US $ Estimated Estimated Start Date Date To Anticipated For personal use only Output U.S p.a. Value(2) Complete Source of Funds U.S $ p.a. Colorado Funding 108,000 galls p.a. $2.7m Q1 2016 Q2 2016 Equity Stage 1 Complete (completed) Colorado Funding ≈2.4
Slide 30: U.S Production Scale-Up - Progress
U.S Production Scale-Up - Progress 30 For personal use only Colorado Production • Stage 2 Scale-up in Colorado scheduled completion March/ April 2017 • Planning for possible, low cost, further expansion of Colorado production to cover any future production shortages until future Georgia plant opens
Slide 31: Colorado Scale-up
31 Colorado Scale-up For personal use only Innovations that work. EDE.ASX
Slide 32: Colorado Scale-up
32 Colorado Scale-up For personal use only Innovations that work. EDE.ASX
Slide 33: CNT in Plastics / Polymers
33 CNT in Plastics / Polymers For personal use only UQ/ Eden- ARC Linkage Research Project Highly Encouraging Preliminary Results with CNT in Nylon 6 • Excellent combination of high modulus (stiffness) and outstanding ductility. • Superior ductility /comparable tensile strength vs super-tough commer
Slide 34: CNT in Plastics / Polymers Cont.
34 CNT in Plastics / Polymers Cont. For personal use only UQ/ Eden- ARC Linkage Research Project Highly Encouraging Preliminary Results with CNT in Nylon 6 • Visual clarity and transparency – potentially suitable for a super-tough- film grade. • Relatively low-cost processing method. • Possible suit
Slide 35: Greg Solomon, Executive Chairman
35 Greg Solomon For personal use only Executive Chairman Level 15, 197 St. Georges Terrace, Perth, Western Australia Tele: +61 8 9282 5889 Email: gsolomon@edeninnovations.com edeninnovations.com EDE.ASX Innovations that work. EDE.ASX
Eden Innovations — Investor Presentation (March 2017) on 6ix